Lung cancer comes in two main types: non-small cell and small cell. Each has different patterns, growth rates, and treatment needs. Smoking is the top risk factor, but…
Kidney cancer affects over 80,000 Americans annually, with renal cell carcinoma as the dominant type. Benjamin R. Lee, MD, MBA, outlines current AUA guideline recommendations, including when to…
NEW YORK (Reuters Health) – In patients newly diagnosed inoperable pancreatic cancer, it’s worth considering celiac plexus neurolysis (CPN) for pain control at the same time that endoscopic…
NEW YORK (Reuters Health) – Postmenopausal women with ovarian cysts detected on ultrasound are not at increased risk of developing ovarian cancer or, for that matter, breast or…
NEW YORK (Reuters Health) – Five-year survival rates are not significantly different for patients with esophagogastric cancer whether they undergo transthoracic or transhiatal esophagectomy, according to the findings…
NEW YORK (Reuters Health) – Pegylated liposomal doxorubicin may be an alternative to paclitaxel in combination with carboplatin for advanced ovarian cancer, based on the results of an…
NEW YORK (Reuters Health) – Whole lung irradiation, used to treat pulmonary metastases of solid malignancies in children, can lead to increasing pulmonary problems, Tennessee-based researchers report in…
NEW YORK (Reuters Health) – Most patients with differentiated thyroid cancer metastasized to bone benefit from iodine-131 therapy, with stabilization of disease and significant reduction in pain, a…
NEW YORK (Reuters Health) – Combining an EGFR-directed tyrosine kinase inhibitor with conventional chemotherapy does not seem to be a good treatment strategy for lung cancer. According to…
NEW YORK (Reuters Health) – Pooled data suggest that cancer patients who are treated with sunitinib (Sutent; Pfizer) have about a 2-fold increased relative risk of developing high-grade…
NEW YORK (Reuters Health) – Nearly 1 in 5 cancer patients treated with cisplatin-based chemotherapy have a thromboembolic event within a month of ending treatment, according to a…
NEW YORK (Reuters Health) – Results of two phase II trials investigating the addition of bortezomib to combination treatments of follicular lymphoma suggest that the strategy is feasible…
